Dr. Liton Kumar Saha | Cancer | Excellence in Research

Dr. Liton Kumar Saha | Cancer | Excellence in Research

Post-doctoral Fellow at Cancer, National Cancer Institute, United States

👨‍🎓He remarkable academic journey, extensive research contributions, and dedication to the field of psychology are truly commendable. Your wealth of knowledge and diverse skill set reflect a deep commitment to understanding and addressing critical issues such as bullying, inclusion, and socialization.

🔬 He successful completion of a PhD in Psychology, along with the numerous advanced courses and workshops, showcases your continuous pursuit of excellence and expertise in your field.

🏆 The awards and recognitions, including the First Place in the Poster Award at the University of Stavanger, underscore the impact of your research and the high regard it holds in the academic community.

Professional Profiles:

Education/Research:

From July 2019 to the present, [Name] has served as a Postdoctoral Fellow (Visiting) at the Developmental Therapeutics Branch, National Cancer Institute, NIH. His research focuses on PARP1, TOP3A, Replication, DNA repair, DNA-protein crosslink, mitochondria, and related topics. He earned his Ph.D. degree in Medical Sciences from the Graduate School of Medicine, Kyoto University, Kyoto, Japan, from 2016 to 2019. His Ph.D. research was conducted in the Department of Radiation Genetics, where he investigated the novel function of genes in DNA repair and DNA damage tolerance. He achieved this by generating mutants in human cell lines using CRISPR/Cas9 and TALEN technology. Prior to his Ph.D., he completed his Master’s degree in medical sciences at the Graduate School of Medicine, Kyoto University, Kyoto, Japan, from 2014 to 2016. His research during this period focused on DNA repair and toxicology, specifically utilizing DNA-repair-deficient cells to identify genotoxins with greater sensitivity and characterizing DNA lesions caused by industrial chemical compounds. He received his Master’s degree in Biochemistry and Molecular Biology from the Faculty of Biological Sciences, University of Dhaka, Dhaka, Bangladesh, in 2007-2008. His dissertation was on the phenotypic and molecular characterization of Salmonella Typhi isolated recently in Bangladesh. He also holds a Bachelor’s degree in Biochemistry and Molecular Biology from the Faculty of Biological Sciences, University of Dhaka, Dhaka, Bangladesh, achieved with distinction, from 2001 to 2006.

🔬 Visiting Research Associate

  • Dr. Samuel H. Wilson lab
  • Genome Integrity and Structure Biology Laboratory
  • National Institute of Environmental Health Sciences (NIEHS), NIH, USA
  • March 2017-May 2017
  • Research Topic: Established In-vitro base excision repair (BER) of CPD lesion-containing DNA (cell-extract based and enzyme-mediated both).

🔬 Visiting Research Associate

  • Professor Ian D Hickson lab
  • Center for Chromosome Stability
  • Institute of Cellular and Molecular Medicine
  • Faculty of Health and Medical Sciences
  • University of Copenhagen, Copenhagen, Denmark
  • September 2015- November 2017
  • Research Topic: Performed and established the protocol for the detection of ultrafine DNA bridges (UFBs) in human TK6 cells using MRE11 mutant.

🔬 Research Assistant

  • Department of Radiation Genetics
  • Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • August 2013- March 2014

🔬 Research Officer

  • International Center for Diarrheal Diseases Research, Bangladesh (ICDDR, B)
  • Dhaka, Bangladesh
  • 2009-2012

Awards:

During the period of 2014 to 2019, [Name] was awarded a Scholarship from the Training Program of Leaders for Integrated Medical System: for Fruitful Healthy-Longevity Society in Japan. Additionally, in 2018, he received a research grant from the Training Program of Leaders for Integrated Medical System at Kyoto University, Japan. Similarly, in both 2017 and 2016, he was also awarded research grants from the same Training Program at Kyoto University, Japan.

Publications:

  1. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II–DNA complexes
    • Authors: H Sasanuma, M Tsuda, S Morimoto, LK Saha, MM Rahman, Y Kiyooka, …
    • Citations: 81
    • Year: 2018
  2. Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC)
    • Authors: Y Sun, S Saha, W Wang, LK Saha, SYN Huang, Y Pommier
    • Citations: 72
    • Year: 2020
  3. Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents
    • Authors: U Jo, IS Senatorov, A Zimmermann, LK Saha, Y Murai, SH Kim, …
    • Citations: 64
    • Year: 2021
  4. Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways
    • Authors: Y Sun, LK Saha, S Saha, U Jo, Y Pommier
    • Citations: 56
    • Year: 2020
  5. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
    • Authors: U Jo, Y Murai, S Chakka, L Chen, K Cheng, J Murai, LK Saha, …
    • Citations: 34
    • Year: 2021
  6. Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1–DNA complexes
    • Authors: LK Saha, Y Murai, S Saha, U Jo, M Tsuda, S Takeda, Y Pommier
    • Citations: 22
    • Year: 2021
  7. Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells
    • Authors: LK Saha, M Wakasugi, S Akter, R Prasad, SH Wilson, N Shimizu, …
    • Citations: 21
    • Year: 2020
  8. The ARK assay is a sensitive and versatile method for the global detection of DNA-protein crosslinks
    • Authors: Q Hu, N Klages-Mundt, R Wang, E Lynn, LK Saha, H Zhang, M Srivastava, …
    • Citations: 21
    • Year: 2020
  9. UBC13-mediated ubiquitin signaling promotes removal of blocking adducts from DNA double-strand breaks
    • Authors: R Akagawa, HT Trinh, LK Saha, M Tsuda, K Hirota, S Yamada, A Shibata, …
    • Citations: 18
    • Year: 2020

 

 

Mr. Waseem Ali | Drug Repurposing | Best Researcher Award

Mr. Waseem Ali : Leading Researcher in Drug Repurposing

PhD Student at Drug Repurposing, Guru Nanak Dev Engineering College, Ludhiana, Punjab, India

He remarkable academic journey, extensive research contributions, and dedication to the field of psychology are truly commendable. Your wealth of knowledge and diverse skill set reflect a deep commitment to understanding and addressing critical issues such as bullying, inclusion, and socialization.

🔬 He successful completion of a PhD in Psychology, along with the numerous advanced courses and workshops, showcases your continuous pursuit of excellence and expertise in your field.

🏆 The awards and recognitions, including the First Place in the Poster Award at the University of Stavanger, underscore the impact of your research and the high regard it holds in the academic community.

Professional Profiles:

Education:

Mr. Waseem Ali achieved academic success throughout his educational journey. In 2011, he secured a First Division in the Matriculation examination from the C.B.S.E. Board, India, with a focus on Science. Continuing his impressive performance, he obtained a Second Division in the Higher Secondary examination in 2013 from the same board. In 2016, he graduated with a Second Division from C.C.S. University, Meerut, specializing in Biotechnology with a focus on molecular biology. His commitment to excellence was further demonstrated in 2018 when he completed his Post Graduation with a First Division from Jamia Hamdard, New Delhi, specializing in Biotechnology with a focus on molecular biology.

Experience:

Mr. Waseem Ali has held several positions in the field of Biotechnology and molecular biology. From 05-08-2022 to 29-12-2022, he served as a Project Assistant at Jamia Hamdard, where he contributed to a project aiming to decipher novel targets of M.tb pathogenesis that manipulate host defenses in compromised hosts. The identified targets may be utilized to develop anti-TB agents effective against drug-resistant isolates. His supervisor during this time was Dr. Javaid A Shaikh. Prior to this, from 15-01-2019 to 04-08-2022, Mr. Ali worked as a Project Assistant at Jamia Hamdard, focusing on determining the effect of FDA-approved drugs against M.tb. He evaluated the efficacy of selected drugs against M.tb in vitro and ex vivo, using molecular docking, simulation, and biophysical methods to predict their binding affinity and effect with target proteins. His supervisors during this period were Prof. S. E. Hasnain and Dr. Sonam Grover. Currently, since 04-01-2021, Mr. Ali is pursuing his Ph.D. at Jamia Hamdard under the guidance of Prof. S. E. Hasnain and Dr. Sonam Grover, focusing on research related to drug repurposing.

Publications:

Mr. Waseem Ali has co-authored several research papers in reputable journals. In “Microbes and Infection” in 2023, he collaborated with Salma Jamal, Rishabh Gangwar, Faraz Ahmed, Isha Pahuja, Rahul Sharma, Ved Prakash Dwivedi, Meetu Agarwa, and Sonam Grover on a paper titled “Unravelling the potential of Triflusal as an anti-TB repurposed drug by targeting replication protein DciA,” which was published on 5.8. In “Molecular Informatics” in 2023, he worked with Salma Jamal, Rishabh Gangwar, Faraz Ahmed, Rahul Sharma, Meetu Agarwal, Javaid Ahmad Sheikh, Abhinav Grover, and Sonam Grover on a paper titled “Targeting of essential mycobacterial replication enzyme DnaG primase revealed Mitoxantrone and Vapreotide as novel mycobacterial growth inhibitors,” which was published on 4.05. Additionally, in “Computational and Structural Biotechnology Journal” in 2021, he contributed to a paper titled “Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis,” co-authored with Pooja Singh, Salma Jamal, Faraz Ahmed, Najumu Saqib, Seema Mehra, Deodutta Roy, Nasreen Z Ehtesham, and Seyed E Hasnain. In “Journal of Translational Medicine” in 2021, Mr. Ali collaborated with Salma Jamal, Priya Nagpal, Abhinav Grover, and Sonam Grover on a paper titled “Computational models for the prediction of adverse cardiovascular drug reactions,” which was published on 8.44.